Remove Blood Pressure Remove Clinical Trials Remove Consumption Remove Document
article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218
article thumbnail

CBD Science Update

Project CBD

Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

5 Times Candy Was Scarier than Cannabis

CannaMD

According to the American Journal of Clinical Nutrition : Our systematic review and meta-analysis of prospective cohort studies and randomized controlled trials provides evidence that sugar-sweetened beverage consumption promotes weight gain in children and adults. Cannabis: 1. Not for the faint of heart.

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

In time, Western civilization caught on, and consumption expanded around the globe. Responsible consumption is key, and in the case of psychedelics – where you could potentially become detached from reality – it’s important to be in a safe space, preferably around people you’re comfortable with.

History 119
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Journal of Psychoactive Drugs.